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Background: Although aggressive endoluminal therapy for superficial femoral artery (SFA) occlusive disease is common-
place, the implications of diabetes mellitus (DM) on long-term outcomes in this population are unclear. We examined the
consequences of endovascular treatment of the SFA in patients with and without DM.
Methods: A database of patients undergoing endovascular treatment of the SFA between 1986 and 2005 was maintained.
Three groups were defined: nondiabetic patients, those with non-insulin-dependent DM (NIDDM), and those with
insulin-dependent DM (IDDM). Intention-to-treat analysis was performed. Results were standardized to TransAtlantic
Inter-Society Consensus (TASC) and Society for Vascular Surgery criteria. Time-dependent outcomes were assessed with
Kaplan-Meier survival analyses. Factor analyses were performed using a Cox proportional hazard model for time-
dependent variables. Data are presented as mean  SD where appropriate.
Results: Endovascular treatment (ie, balloon angioplasty  adjuvant stenting in 38%) was initiated in 525 limbs in 437
patients (68% male; average age, 66  14 years) for claudication failing conservative therapy or chronic critical limb
ischemia (CLI). Of these, 50% were nondiabetic, 26% had NIDDM, and 24% had IDDM. Analyses were separated by
those presenting with claudication (61%) and those presenting with CLI (39%). Among patients presenting with
claudication, those with IDDM had significantly lower assisted primary patency (P < .01) and a higher incidence of
restenosis (P  .04). Patencies at 3 years for nondiabetic, NIDDM, and IDDM were 62%, 72%, and 54% (primary), and
81%, 86%, and 65% (assisted primary), respectively. Patency and restenosis rates were associated with lesion calcification,
TASC D lesion categorization, and acute periprocedural occlusion. Among patients presenting with CLI, patency and
restenosis rates were equivalent across all groups; however, limb salvage was significantly worse for both groups of
diabetic patients compared with nondiabetic (NIDDM, P  .01; IDDM, P  .02). Reduction in limb salvage rates was
associated with presence of tissue loss at presentation, end-stage renal disease, and progression of distal disease on
follow-up.
Conclusions: Endoluminal therapy for SFA occlusive disease yields lower assisted patency rates and higher restenosis rates
for those patients presenting with claudication who have more advanced diabetes (ie, IDDM). Among those patients
presenting with CLI, particularly those with tissue loss, limb salvage rates are lowered for the diabetic groups (NIDDM
and IDDM) despite equivalent patency and restenosis rates. ( J Vasc Surg 2007;46:946-58.)Diabetes mellitus (DM) is a significant known risk
factor for peripheral arterial disease and is increasing in
incidence and prevalence.1 Similar to nondiabetic patients,
a typical distribution of atherosclerotic occlusive disease
develops in these patients that is accelerated by their dia-
betic disease and also often presents with a classically de-
scribed preponderance of tibial disease.2 In addition, dia-
betic patients may be further burdened with a functional
microvascular deficiency, typified by the diabetic foot, al-
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946though not truly small vessel occlusive lesions as historically
described.3
As is the case for patients without DM, atherosclerotic
occlusive disease of the superficial femoral artery (SFA) can
lead to claudication, which may evolve to chronic critical
limb ischemia (CLI). All patients with claudication require
aggressive risk-factor modification and should be placed on
exercise programs, whereas interventions are reserved for
failures of this therapy. The standard of care for CLI is
revascularization, if possible.
In the last several years, the treatment of SFA occlusive
disease has undergone a shift in management, and endolu-
minal therapy is increasingly being performed as first-line
therapy. Although the body of evidence for lower extremity
bypasses in the setting of DM does not seem to support any
difference in outcomes relative to nondiabetic patients, the
influence of endoluminal therapy on outcomes in diabetic
patients is not well characterized. The aim of this study is to
examine the consequences of endovascular treatment of the
SFA in patients with DM.
METHODS
Experimental design. A database was maintained of
patients undergoing percutaneous transluminal angioplasty
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2005. Patients were divided into three groups: those with-
out DM, those withDMwho do not receive insulin therapy
(non-insulin-dependent DM [NIDDM]), and those with
DM who receive insulin as part of their routine diabetes
management (insulin-dependent DM [IDDM]. DM was
defined as a fasting plasma glucose level110 mg/dL or a
glycosylated hemoglobin A1c level 7%.
Methodology. For each patient captured, demo-
graphics, symptoms, existing comorbid conditions, and risk
factors for atherosclerosis were identified. All patients with
claudication were encouraged to exercise daily, and their
risk factors were identified and corrected through their
primary care providers. Patients on these regimens who
experienced tissue loss or deteriorating symptoms were
offered endoluminal intervention. Patients with critical
ischemia were treated within the same hospitalization.
Therapy for individual patients was dictated by individual
attending physician preference and was not regulated by
unit guidelines.
All patients received aspirin daily (81 mg or 325 mg)
as a general cardiovascular protection agent. Three patients
(0.7%) were taking Coumadin (Bristol-Myers Squibb,
Princeton, NJ) at the time of the intervention, and this was
continued after the procedure.
Noninvasive studies were performed initially; however,
patients with serious symptoms or signs of severe stenosis or
occlusion as determined by the initial noninvasive tests
received angiograms. Angiograms and angiographic re-
ports were reviewed, lesions were categorized under the
TransAtlantic Inter-Society Consensus (TASC) system,4
and the distal runoff was scored. Assessment of lesion
calcification was determined by the operator and consid-
ered positive if calcified atheroma was present at the pri-
mary treatment site on fluoroscopy.
Angioplasty was performed under systemic heparin ad-
ministration (40 to 60 U/kg), and completion angiogra-
phy was performed to assess the technical result. Stents
were used at the discretion of the operator for flow-limiting
dissections (grade C or higher), intimal flaps, acute occlu-
sions, or poor technical results (30% residual stenosis).
No procedures or interventions were performed that could
have potentially jeopardized the outflow vessel. A glycop-
rotein (GP) IIb/IIIa inhibitor (abciximab, 3.75 g/kg/hr
for 12 hours) was used at the discretion of the primary
operator when thought to provide benefit.
Patients who had a successful endoluminal intervention
received 75 mg of clopidogrel. While a patient was taking
clopidogrel, aspirin therapy was maintained at 81 mg/d.
Patients who were already taking clopidogrel before the
intervention continued to do so after the intervention.
Patients underwent routine duplex follow-up at 1, 3,
and 6 months after the procedure, and every 6 months
thereafter. During follow-up, angiograms were only per-
formed if noninvasive studies suggested restenosis or occlu-
sion in the presence of recurrent symptoms or tissue loss.
Symptom recurrence was determined informally by
patient interview during clinical follow-up. Restenosis wasdefined as 50% decrease in postintervention luminal di-
ameter seen on noninvasive imaging or angiography. A
vessel was considered patent if it was free from occlusion by
noninvasive imaging or angiography, or both. Reinterven-
tion was also considered a failure of primary patency, and
assisted patency included the time of added patency after
repeat endovascular intervention.
Definitions. Coronary artery disease was defined as a
history of angina pectoris, myocardial infarction, conges-
tive heart disease, or prior coronary artery revasculariza-
tions. Cerebrovascular disease was defined as a history of
stroke, transient ischemic attack, or carotid artery revascu-
larization. NIDDM was defined as any patient with DM
who did not routinely receive insulin therapy for diabetes
management. IDDM was defined as any patient with DM
who routinely received insulin therapy. TASC classification
of disease severity for femoral lesions was used to define the
categories of lesions.
A death 30 days of the procedure was considered
procedure-related. Amajor complication was defined as any
event, regardless of how minimal, not routinely observed
after endoluminal therapy that required treatment with a
therapeutic intervention or rehospitalization 30 days of
the procedure.
Runoff at the tibial level was determined by the number
of patent vessels present, with a maximum of three (scored
as 0, 1, 2, or 3).
Statistical analysis. All statistical analyses were per-
formed on an intention-to-treat basis. Measured values are
reported as percentages or means SD. Limb salvage rates
are calculated using Kaplan-Meier analysis and reported
using current Society for Vascular Surgery (SVS) criteria.5
Standard errors are reported in Kaplan-Meier analyses. Cox
proportional hazard analyses were performed to identify
factors associated with outcomes. Analyses were performed
using JMP 5.0.1 software (SAS Institute, Cary, NC).
RESULTS
Patient population. During the study period, 525
limbs in 437 patients underwent endoluminal treatment
(ie, balloon angioplasty  adjuvant stenting) of the super-
ficial femoral artery. Treatment occurred in 265 limbs of
219 nondiabetic patients (50% of patients), 133 limbs in
114 NIDDM patients (26% of patients), and 127 limbs in
104 IDDM patients (24% of patients). The proportion of
patients within each of these groups presenting with clau-
dication vs CLI differed significantly, with claudicant pa-
tients comprising 74% of nondiabetic patients, 52% of
NIDDM patients, and 43% of IDDM patients.
Patients presenting with claudication. Of the over-
all 525 limbs treated, 319 limbs in 256 patients were
treated for disabling claudication (SVS grade 1 to 3); 196
limbs were treated among 158 nondiabetic patients (50% of
patients), 69 limbs were treated in 56 NIDDM patients
(26% of patients), and 54 limbs were treated in 42 IDDM
patients (24% of patients). The nondiabetic, NIDDM, and
IDDM groups did not differ with respect to average age
(66  11 years, 69  11 years, and 62  10 years,
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betic (78% male) and NIDDM (71% male) groups and
significantly different for the IDDM group (61% male; P
.01 relative to nondiabetic group). The NIDDM group
differed significantly from the nondiabetic group in only
two of the comorbidities identified: fewer had cerebrovas-
cular disease at 15% vs 29%, respectively (P .02) andmore
had hyperlipidemia at 75% vs 54%, respectively (P 0.01).
However, the IDDM group differed from the nondiabetic
group in each comorbidity monitored, with significantly
greater rates of coronary disease, congestive heart disease,
myocardial infarction history, cerebrovascular disease, hy-
perlipidemia, and end-stage renal disease (P  0.05 for all
risk factors; Table I).
Claudicant periprocedural variables. Most lesions
treated were categorized as either TASC A or B in all
groups (nondiabetic, 68%; NIDDM, 65%; IDDM, 83%),
but were significantly more common within the IDDM
group relative to the nondiabetic group (P  .03). Lesion
calcification was not significantly different among the
groups: nondiabetic, 59%; NIDDM, 62% (P  .60); and
IDDM, 57% (P  .87). Tibial vessel runoff for the nondi-
abetic, NIDDM, and IDDM groups was equivalent and
averaged 2.3 0.7, 2.0 0.7, and 2.2 0.7, respectively,
and the number of patients with zero or one tibial vessel
runoff for each of these groups was 16%, 20% (P  .39),
and 17% (P  .88), respectively.
Location of disease within the superficial femoral and
popliteal arteries did not differ between groups (Table II).
Preoperative resting ankle-brachial indices (ABI) averaged
0.66 0.15 for the nondiabetic group, 0.61 0.18 for the
NIDDM group, and 0.62  0.22 for the IDDM group
(P  0.6 among all groups). The proportion of patient
Table I. Characteristics of patients presenting with
claudication
Characteristics Nondiabetic NIDDM IDDM
Demographics
Patients, No. 158 56 42
Limbs treated, No. 196 69 54
Male, % 78 71 61*
Average age, y  SD 66  11 69  11 62  10
Follow-up, y  SD 1.7  2.1 1.6  2.2 2.4  3.1
Comorbidities
Smoking history, % 96 100 89*
Current smoker, % 20 21 11*
CAD, % 53 61 72*
History of MI, % 52 61 70*
CHD, % 20 20 52*
Hypertension, % 86 90 69*
CVD, % 29 15* 44*
ESRD, % 0 0 7*
Hyperlipidemia, % 54 75* 69*
NIDDM, Non-insulin-dependent diabetes mellitus; IDDM, insulin-
dependent diabetes mellitus; CAD, coronary artery disease; MI, myocar-
dial infarction; CHD, congestive heart disease; CVD, cerebrovascular
disease; ESRD, end-stage renal disease.
*P  .05 relative to the nondiabetic group.limbs requiring adjunctive inflow or outflow proceduresdid not differ among the groups (Table II). Likewise, the
proportion of lesions requiring adjuvant stenting was not
significantly different among the groups: nondiabetic, 41%;
NIDDM, 45% (P  .60); and IDDM, 30% (P  .12).
Claudicant morbidity and mortality. Overall mor-
bidity, site-specific morbidity, and access morbidity were
not significantly different between diabetic and nondiabetic
groups (Appendix Table EI, online only). Overall 30-day,
all-cause mortality was 0% to 2% between groups and was
not significantly different (Appendix Table EI, online
only). Likewise, overall actuarial survival by Kaplan-Meier
analysis was not significantly different between groups, with
nondiabetic, NIDDM, and IDDM 5-year survival rates of
78% 6%, 83% 9% (P .59), and 74% 9% (P .56),
respectively (Appendix Fig E1, online only).
Claudicant outcomes. The initial technical failure
rate was 5%, 6% (P  .82), and 9% (P  .26) for the
nondiabetic, NIDDM, and IDDM groups, respectively.
Most in all groups had a postprocedure rise in ABI of
0.10, although significantly fewer were in the IDDM
group than in the nondiabetic group (nondiabetic, 80%;
NIDDM, 74%; P  .28; IDDM, 67%; P  .04). An
equivalent number of patients in all groups reported either
symptom improvement or resolution, with nondiabetic,
87%; NIDDM, 87% (P .95); and IDDM, 83% (P .46).
Primary patency was equivalent between nondiabetic,
NIDDM, and IDDM groups, with 3-year primary patency
rates of 62%  5%, 72%  7% (P  .66), and 54%  9%
(P  .19), respectively (Fig 1). Assisted primary patency
(Fig 2) and freedom from restenosis (Fig 3) were equivalent
for the NIDDM group (P .79 and P .89, respectively)
relative to the nondiabetic group, but were both were
significantly lower for the IDDM group (P  .01 and P 
.04, respectively) compared with the nondiabetic group
(Table III).
Cox proportional hazards analysis was used to evaluate
the impact of preoperative and perioperative factors for
each of the primary outcomes measured. The factors signif-
Table II. Location of disease and adjunctive procedures
in patients presenting with claudication
Variable Nondiabetic* NIDDM IDDM
Disease location
Proximal SFA, % 24 35 28
Mid SFA, % 37 39 24
Distal SFA, % 59 48 44
Popliteal, % 24 14 17
Adjunct procedures
Aortoiliac intervention, % 8 7 6
Tibial Intervention, % 1 0 0
Thrombolysis/
embolectomy, % 3 6 6
NIDDM,Non-insulin-dependent diabetes mellitus; SFA, superficial femoral
artery.
*P  .05 relative to the nondiabetic group for each NIDDM and IDDM
value.icantly associated with a reduction in primary patency were
tic gr
pariso
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.03), TASC D lesion categorization (RR, 5.01; P  .01),
and acute occlusion at the time of primary intervention
Fig 1. Primary patency curves for patients without di
(NIDDM, gray line), and insulin-dependent diabetes m
Primary patency is not significantly different between gro
and IDDM groups are in comparison with the nondiabe
Fig 2. Assisted patency curves for patients without di
(NIDDM, gray line), and insulin-dependent diabetes m
Assisted patency is significantly lower for IDDMpatients
P values for the NIDDM and IDDM groups are in com(RR, 2.77; P  .04). These same factors were significantlyassociated with reduced assisted primary patency (calcifica-
tion: RR, 1.83 [P  .02]; TASC D: RR, 6.35 [P  0.01];
occlusion: RR, 4.99 [P  0.01]) and reduced freedom from
s (black line), non-insulin-dependent diabetes mellitus
s (IDDM, light gray line) presenting with claudication.
by Kaplan-Meier analysis. The P values for the NIDDM
oup.
s (black line), non-insulin-dependent diabetes mellitus
s (IDDM, light gray line) presenting with claudication.
e to non-diabetic patients by Kaplan-Meier analysis. The
n with the nondiabetic group.abete
ellitu
upsabete
ellitu
relativrestenosis (calcification: RR, 1.83 [P  .02]; TASC D: RR,
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stenting was not associated with a change in patency or
restenosis rates. Additional variables analyzed are presented in
Appendix Table EII (online only).
Patients presenting with critical limb ischemia. Of
the overall 525 limbs treated, 206 limbs in 181 patients
were treated for CLI (SVS grade 4 to 6); 69 limbs were
treated among 62 nondiabetic patients (34% of patients),
64 limbs were treated in 56 NIDDM patients (31% of
patients), and 73 limbs were treated in 63 IDDM patients
Fig 3. Freedom from restenosis curves for patients wi
mellitus (NIDDM, gray line), and insulin-dependent
claudication. Freedom from restenosis is significantly lo
Kaplan-Meier analysis. The P values for the NIDDM a
group.
Table III. Patency and freedom from restenosis rates in p
End point 1 Year, %
Primary patency
Nondiabetic 77  3
NIDDM 77  6
IDDM 64  7
Assisted patency
Nondiabetic 88  3
NIDDM 86  5
IDDM† 70  7
Freedom from restenosis
Nondiabetic 79  3
NIDDM 73  7
IDDM† 62  7
NIDDM, Non-insulin-dependent diabetes mellitus; IDDM, insulin-depend
Data are presented as mean  SD.
*P-values for NIDDM and IDDM groups are based on Kaplan-Meier analy
†P  .05 relative to the nondiabetic group.(35% of patients). The proportion of these limbs presentingwith tissue loss did not differ significantly among the
groups, with nondiabetic, 61%; NIDDM, 73% (P  .12);
and IDDM, 68% (P  .34). The nondiabetic, NIDDM,
and IDDM groups did not differ with respect to average
age (69  14 years, 69  14 years, and 62  13 years,
respectively). Gender was also equivalent between nondia-
betic (61% male), NIDDM (64% male, P  .70), and
IDDM groups (66% male, P  .55).
Among various comorbidities, the NIDDM and
IDDM groups had significantly higher rates of congestive
diabetes (black line), non-insulin-dependent diabetes
tes mellitus (IDDM, light gray line) presenting with
for IDDM patients relative to nondiabetic patients by
DM groups are in comparison with the non-diabetic
ts presenting with claudication
3 Years, % 5 Years, % P*
62  5 51  7 —
72  7 72  7 .6575
54  9 47  11 .1859
81  4 77  5 —
86  5 86  5 .7915
65  8 56  10 .0075
57  6 47  7 —
68  8 55  14 .8900
43  9 37  10 .0356
abetes mellitus.
mpared with the nondiabetic group.thout
diabe
wer
nd IDatien
ent di
sis coheart disease and hyperlipidemia relative to the nondiabetic
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NIDDM group (97%, P  .02) compared with the nondi-
abetic group (86%). The presence of end-stage renal disease
requiring hemodialysis was significantly more common
within the IDDM group (30%, P  0.01) relative to the
nondiabetic group (9%). The other comorbidities identi-
fied were equivalent between groups (Table IV).
Critical limb ischemia periprocedural variables.
Lesions were categorized as TASC A or B in 56% of
nondiabetic limbs presenting with CLI and TASC C or D
in 44%, which was significantly different from both diabetic
groups. TASC C or D lesions predominated in the
NIDDM group (62%, P  .03) and significantly more
TASC A or B lesions were in the IDDM group (73%, P 
.04). The presence of lesion calcification was not signifi-
cantly different between groups, with nondiabetic, 72%;
NIDDM, 84% (P  .10); and IDDM, 78% (P  .44).
Tibial vessel runoff for the nondiabetic, NIDDM, and
IDDMgroups was equivalent and averaged 1.8 0.8, 1.8
0.9, and 1.7 0.8, respectively, and the number of patients
with zero or one tibial vessel runoff for each of these groups
was 33%, 42% (P  .29), and 42% (P  .26), respectively.
Disease location was also similar between groups, with the
exception of a greater incidence of mid-SFA lesions in the
NIDDM group (62%) than in the nondiabetic group (41%;
P  .01).
Preoperative resting ABIs averaged 0.51 0.23 for the
nondiabetic group, 0.47  0.22 for the NIDDM group,
and 0.45  0.24 for the IDDM group (P  NS among all
groups). The portion of patient limbs requiring adjunctive
infloworoutflowprocedures didnot differ among thegroups,
with the exception of a significantly greater portion of
NIDDM limbs (19%) requiring thrombolysis or embolec-
Table IV. Characteristics of patients presenting with
critical limb ischemia
Characteristics Nondiabetic NIDDM IDDM
Demographics
Patients, No. 158 56 42
Limbs treated, No. 69 64 73
Male, % 61 64 66
Average age, y  SD 70  14 69  14 62  13
Follow-up, y  SD 1.3  1.5 1.1  1.5 1.8  2.4
Comorbidities
Smoking history, % 86 97* 88
Current smoker, % 25 17 10*
CAD, % 61 52 70
History of MI, % 51 47 63
CHD, % 20 38* 59*
Hypertension, % 84 92 84
CVD, % 26 28 38
ESRD, % 9 9 38*
Hyperlipidemia, % 38 55* 64*
NIDDM, Non-insulin-dependent diabetes mellitus; IDDM, insulin-
dependent diabetes mellitus; CAD, coronary artery disease; MI, myocar-
dial infarction; CHD, congestive heart disease; CVD, cerebrovascular
disease; ESRD, end-stage renal disease.
*P  .05 relative to the nondiabetic group.tomy, or both, than those of the nondiabetic group (7%, P.05). The portion of lesions requiring adjuvant stenting was
not significantly different between groups (Table V), with
nondiabetic, 30%; NIDDM, 45% (P  .08); and IDDM,
33% (P  .76).
Critical limb ischemia morbidity and mortality.
Overall systemicmorbidity, access site morbidity, and treat-
ment site morbidity were not significantly different be-
tween the subgroups and were 8% for any complication
(Appendix Table EIII, online only). Overall 30-day, all-
cause mortality was 5% to 7% between groups and was not
significantly different. Likewise, overall actuarial survival by
Kaplan-Meier analysis was not significantly different between
groups, with nondiabetic, NIDDM, and IDDM 1-year sur-
vival rates of 81% 5%, 75% 7% (P .50), and 73% 6%
(P  .58), respectively (Appendix Fig E2, online only).
Critical limb ischemia outcomes. The initial techni-
cal failure rate was 13%, 9% (P .50), and 5% (P .12) for
the nondiabetic, NIDDM, and IDDM groups, respec-
tively. A majority and equivalent portion of diabetic limbs
and nondiabetic limbs had a postprocedure rise in ABI of
0.10, with nondiabetic, 71%; NIDDM, 83% (P  .11);
and IDDM, 67% (P  .62). An equivalent number of
patients in all groups reported symptom improvement or
resolution, with nondiabetic, 78%; NIDDM, 77% (P 
.81); and IDDM, 70% (P  .25).
Primary patency was equivalent among nondiabetic,
NIDDM, and IDDM groups, with respective 2-year pri-
mary patency rates of 44% 10%, 45% 9% (P .68), and
57%  7% (P  .48; Fig 4). At 2 years, the assisted primary
patency (Fig 5) also was equivalent among groups, with
respective rates of 58%  8%, 58%  10% (P  .88), and
65%  7% (P  .56), as was freedom from restenosis
(Fig 6), with respective rates of 47%  9%, 38%  9% (P 
.48), and 51%  8% (P  .44). Finally, survival was not
significantlyworse for the diabetic groups, with 5-year survival
rates of 29%  12%, 37%  13% (P  .50), and 40%  8%
(P  .58), respectively (Appendix Fig E2, online only).
Limb salvage was significantly reduced for those pa-
tients presenting with CLI who had NIDDM (P  .01) or
Table V. Location of disease and adjunctive procedures
in patients presenting with critical limb ischemia
Characteristic
Nondiabetic,
%
NIDDM,
%
IDDM,
%
Disease location
Proximal SFA 33 48 37
Mid SFA 41 63* 54
Distal SFA 51 66 58
Popliteal 32 52* 30
Adjunct procedures
Aortoiliac Intervention 13 5 4
Tibial intervention 4 3 7
Thrombolysis/embolectomy 7 19* 8
NIDDM, Non-insulin-dependent diabetes mellitus; IDDM, insulin-
dependent diabetes mellitus; SFA, superficial femoral artery.
*P  .05 relative to the nondiabetic group.IDDM (P  .02) relative to nondiabetic patients (Fig 7).
non-
non-
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years was 89%  4%, and was 61%  9% for NIDDM
patients and 61% 8% for IDDM patients. When compar-
Fig 4. Primary patency curves for patients without di
(NIDDM, gray line), and insulin-dependent diabetes m
ischemia. Primary patency is not significantly different be
NIDDM and IDDM groups are in comparison with the
Fig 5. Assisted patency curves for patients without di
(NIDDM, gray line), and insulin-dependent diabetes m
ischemia. Assisted patency is not significantly different be
NIDDM and IDDM groups are in comparison with theing only those patients in each group presenting with restpain, the difference did not persist for the NIDDM (P 
.51) or IDDM groups (P  .92).
However, evaluating the proportion of patients
s (black line), non-insulin-dependent diabetes mellitus
s (IDDM, light gray line) presenting with critical limb
n groups by Kaplan-Meier analysis. The P values for the
diabetic group.
s (black line), non-insulin-dependent diabetes mellitus
s (IDDM, light gray line) presenting with critical limb
n groups by Kaplan-Meier analysis. The P values for the
diabetic group.abete
ellitu
tweeabete
ellitu
tweewithin each group presenting with tissue loss yields a
rison
IDD
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NIDDM (P 0.01) and IDDM groups (P 0.01), with
respective 2-year limb salvage rates of 57%  10% and
Fig 6. Freedom from restenosis curves for patients wi
mellitus (NIDDM, gray line), and insulin-dependent dia
limb ischemia. Freedom from restenosis is not significan
values for the NIDDM and IDDM groups are in compa
Fig 7. Limb salvage curves for patients without diab
(NIDDM, gray line), and insulin-dependent diabetes m
ischemia. Limb salvage is significantly lower for NIDD
Kaplan-Meier analysis. The P values for the NIDDM and49%  13%. This difference also persists when hemodi-alysis-dependent patients are excluded from the analysis
of patients presenting with tissue loss (P  .01 for
NIDDM and IDDM groups relative to the nondiabetic
diabetes (black line), non-insulin-dependent diabetes
mellitus (IDDM, light gray line) presenting with critical
ferent between groups by Kaplan-Meier analysis. The P
with the non-diabetic group.
(black line), non-insulin-dependent diabetes mellitus
s (IDDM, light gray line) presenting with critical limb
d IDDM patients relative to non-diabetic patients by
M groups are in comparison with the nondiabetic group.thout
betes
tly difetes
ellitu
M angroup). Outcomes are summarized in Table VI.
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taken to investigate the impact of preoperative and periop-
erative factors related to the outcomes of primary and
assisted patency, freedom from restenosis, and limb salvage.
Like in the subset with claudication, lesion calcification
(RR, 1.22; P  .01), TASC D lesion categorization (RR,
2.37; P  .01), and acute occlusion at the initial interven-
tion (RR, 3.85; P  0.01) were again noted to be signifi-
cantly associated with reductions in primary patency, as was
the presence of tissue loss at presentation (RR, 1.73; P 
.03). These factors were also significantly associated with
reductions in freedom from restenosis, with respective RRs
of 2.93 for calcification (P  .01), 2.55 for TASC D (P 
0.01), and 3.82 for occlusion (P  .01). Factors signifi-
cantly associated with a reduction in assisted primary pa-
tency also included calcification (RR, 3.08; P  .01) and
TASC D lesions (RR, 2.11; P  .02), although occlusion
was not significantly associated.
Tissue loss at presentation trended toward, but did not
achieve, the conventional level of statistical significance for
assisted primary patency (P  .055) and freedom from
restenosis (P  .068). With respect to limb salvage, four
factors were significantly associated with a reduction in
rates: end-stage renal disease on dialysis (RR, 2.28; P 
.04), presence of tissue loss at presentation (RR, 2.11; P
.04), zero or one vessel tibial runoff vs two or three vessel
runoff (RR, 3.23; P  .01), and progression of distal
disease noted in follow-up (RR, 3.86; P  0.01). Notable
factors that were not significantly associated included lesion
calcification (P .31), TASC D lesion categorization (P
.25), acute occlusion at initial intervention (P  .80), and
adjuvant stenting (P  .89). Additional variables analyzed
Table VI. Patency, restenosis, and limb salvage rates in pa
End point 1 Year, %
Primary patency
Nondiabetic 63  7
NIDDM 56  7
IDDM 61  6
Assisted patency
Nondiabetic 71  6
NIDDM 66  7
IDDM 69  7
Freedom from restenosis
Nondiabetic 63  7
NIDDM 52  8
IDDM 66  7
Limb salvage
Nondiabetic 89  4
NIDDM† 67  8
IDDM† 73  6
NIDDM, Non-insulin-dependent diabetes mellitus; IDDM, insulin-depend
Data presented as mean  SD.
*P values for NIDDM and IDDM groups are based on Kaplan-Meier analy
†P  .05.are presented in Appendix Table EIV (online only).DISCUSSION
A significant portion of the modern vascular practice
consists of diabetic patients, and the prevalence of these
patients is increasing. On the basis of data from the 1999-
2000 National Health and Nutrition Examination Survey
(NHANES), Selvin and Erlinger6 identified a 26.4% prev-
alence of diabetic patients among those found to have
peripheral arterial disease (PAD), whereas those without
PAD had a DM prevalence of only 10.1%. Among patients
with a more advanced limb ischemia grade, the prevalence
of DM is often higher.7-9 Furthermore, after monitoring
increases in the incidence of DM as well as declining
mortality among diabetic patients, investigators from the
Division of Diabetes Translation at the CDC recently pro-
jected that the total number of individuals diagnosed with
DMwill increase by 198% between 2005 and 2050 and the
total prevalence will more than double from 5.62% to
12.00%.1
Although the mechanism(s) by which hyperglycemia
and its metabolic byproducts mediate their pathophysio-
logic changes is not fully characterized,10 its status as a
significant risk factor for atherosclerotic peripheral vascular
disease has been demonstrated.11 Selvin and Erlinger noted
that in age-adjusted and gender-adjusted logistic regression
analyses of the aforementioned NHANES data, DM con-
ferred a risk ratio of 2.71 for the development of PAD; yet,
other factors such as current smoking, hypertension, hyper-
cholesterolemia, and kidney disease have also been signifi-
cantly associated with the development of PAD.6 What has
distinguished DM-associated PAD has been its classic de-
scription of a more distal distribution of atherosclerotic
disease affecting the infrageniculate arteries while sparing
s presenting with critical limb ischemia
2 Years, % 3 Years, % P*
44  10 30  14 —
45  9 45  9 .6807
57  7 57  7 .4808
58  8 58  8 —
58  1 58  10 .8833
65  7 65  7 .5641
47  9 39  10 —
38  9 38  9 .4793
51  8 45  9 .4386
89  4 89  4 —
61  9 31  22 .0123
61  8 61  8 .0184
abetes mellitus.
comparison with the nondiabetic group.tient
ent di
sis inthe foot arteries, and this is likely further affected by hyper-
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basement membrane thickening and functional microvas-
cular impairment.2,3,10,12 It is this characterization that has
provided the impetus for reviewing our experience in treat-
ing SFA disease by way of endoluminal therapy.
In separating our diabetic patients in NIDDM and
IDDM groups, we assumed that those taking more insulin
have more severe DM, in that they have less endogenous
insulin reserve and a history of less well controlled dysme-
tabolism.13 At the least, diabetic patients receiving exoge-
nous insulin therapy have manifested an increased rate of
cardiovascular events and cardiovascular mortality com-
pared with those not receiving insulin therapy in some
studies.13,14 Insulin has also demonstrated mitogenic activ-
ity, causing smooth muscle cell proliferation and hyperpla-
sia.15,16 In addition, it increases low-density lipoprotein
receptor activity and can decrease high-density lipoprotein
receptor-mediated cholesterol efflux.15
Some have concluded, however, that insulin therapy is
not atherogenic of itself but rather a marker of more severe
DM.17 Clearly insulin resistance and the subsequent need
for exogenous insulin therapy occurs within a complex of
associated metabolic abnormalities including obesity, dys-
lipidemia, and hypertension, and these factors collectively
impact vascular disease. Although any negative effect from
insulin therapy is likely counterbalanced by the benefits of
glycemic control,13 we hoped to stratify our diabetic pa-
tients into those with greater or lesser disease to better
evaluate the effect of diabetes in these differing patient
groups.
Our results can be summarized into these major points:
1. With respect to patients presenting with claudication,
the NIDDM patients did not have significantly different
outcomes relative to nondiabetic patients, be it compli-
cations, patency, or symptom recurrence.
2. Patients within the IDDM subgroup tended to have a
greater systemic vascular disease burden based on their
comorbidities and also had increased rates of restenosis
and decreased assisted primary patency despite having
less complex lesions according to the TASC system of
categorization.
3. Among patients presenting with CLI, those in the
NIDDM and IDDM subgroups had equivalent patency
and restenosis rates but significantly lower limb salvage
rates than the nondiabetic patients, and this significant
reduction persisted when evaluating only those with
tissue loss and excluding patients on dialysis.
Of interest was that we did not find overall survival differ-
ences between diabetic and nondiabetic patients when re-
sults were analyzed according to mode of presentation.
Patients presenting with claudication. In agreement
with recent reports of endoluminal therapy for infraingui-
nal atherosclerotic disease, we report low rates of major
morbidity, low rates of 30-day all-cause mortality (0% to
2%), and no periprocedural deaths. In fact, despite signifi-
cantly higher rates of coronary disease, history of myocar-
dial infarction, end-stage renal disease, and hyperlipidemia(and lower rates of smoking, hypertension, and men) for
the IDDM group, overall actuarial survival was equivalent
among the three subgroups and in line with the overall
reports of others, although DM has previously been noted
as a factor associated with decreased survival according to
Cox multiple regression analysis.18,19 The reason for equiv-
alent survival between diabetic and nondiabetic patients is
not clear, but may relate to differences in other risk factors
among the groups. Nonetheless, the overall excellent sur-
vival across all subgroups, coupled with minimal morbidity,
continues to support the role of endoluminal intervention
as first-line therapy for lifestyle-limiting claudication.
Whereas survival was equivalent between diabetic and
nondiabetic patients, we found differences in assisted pri-
mary patency and freedom from restenosis between the
IDDM group and the nondiabetic patients. The 3-year
primary patency in this study was 62%  5% for the nondi-
abetic group, 72% 7% for the NIDDMgroup, and 54%
9% for the IDDM group. These primary patency results are
in agreement with a recent meta-analysis of 19 studies
deriving 3-year primary patency rates of 61% for angioplasty
of the SFA in patients presenting with claudication, al-
though DM was not evaluated as a risk factor.20
The 3-year assisted primary patency in our study was
81%  4%, 86%  5%, and 65%  8%, respectively and, in
this case, significantly lower for the IDDM group. The
results for our nondiabetic group are in agreement with
those reported for claudicant patients by Conrad et al18 at a
3-year assisted primary patency rate of 92.6%. These results
differ with the secondary patency of 50% reported by Jam-
sen et al,19 likely because the Jamsen study population
encompassed patients with longer lesion lengths and more
occlusions requiring recanalization than have most other
reports. A history of DM was not significantly associated
with patency in the Conrad (31% diabetic subjects) or
Jamsen (25% subjects) studies.
We suspect that our findings of reduced assisted pri-
mary patency in IDDMpatients, but not NIDDMpatients,
are not inconsistent with the Jamsen and Conrad studies
and instead reflect a more substantial degree of diabetes-
induced change and progression concentrated in the
IDDM subgroup. We cannot, unfortunately, reliably com-
pare our results with several other reports on endoluminal
therapy for femoropopliteal atherosclerotic disease because
they typically involve a mix of patients with claudication
and CLI, the latter being associated with worse out-
comes.21
Patients presenting with critical limb ischemia.
Similar to other reports, we identified lower patency and
freedom from restenosis rates for patients presenting with
CLI than for patients presenting with claudication.18,22 At
2 years, our nondiabetic, NIDDM, and IDDM groups had
respective primary patency rates of 44% 10%, 45%  9%,
and 57%  7%. These results are, like those for claudicant
patients, in line with the meta-analysis of Muradin et al,20
who derived 2-year primary patency rates of 36% to 49% for
CLI patients having angioplasty and 65% to 66% for CLI
patients having primary stenting. Given that most of our
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among groups), it is not surprising that our results more
closely paralleled those in the meta-analysis that had angio-
plasty only.
Unlike our results for claudicant patients in this study,
we found no significant differences between diabetic and
nondiabetic patients presenting with CLI concerning as-
sisted patency or restenosis rates. Other reports on this
matter within the literature have been inconsistent. Several
authors have recently reported on mixed claudicant and
CLI patients as well as only CLI patients whereDMwas not
significantly associated with patency.8,18,22 In contrast,
others have reported an association between IDDM and
patency failure.23,24 Clouding this issue are a number of
confounding variables that are difficult to control in retro-
spective series, including this report. Clearly, lesion sever-
ity, lesion calcification, kidney disease, and lesion occlusion
carry the potential to confound results for patency and
restenosis, some of which were different among our groups
(lesion severity was greater for NIDDM and lesser for
IDDM).
The impact of DM on limb salvage rates for endovas-
cular therapy has been inconsistent. Overall, reported
1-year limb salvage rates for endovascular therapy have
ranged from 75% to 91%8,18,23-25 compared with our
1-year limb salvage rates of 89% for nondiabetic patients,
67% for NIDDM patients (P  .01), and 73% for IDDM
patients (P  .02). Several authors have reported no asso-
ciation between DM and reduced limb salvage rates, al-
though the patient populations evaluated in each of these
studies varied considerably.7,8,24 In contrast, Conrad et
al18 identified DM as being significantly associated with
limb loss, conferring a hazard ratio of 11.5; however, their
results must be interpreted with caution because the anal-
ysis appears to have included claudicant patients in addition
to those with CLI, and the CLI group had significantly
more patients with DM.
As is the case for endovascular therapy, the effect of DM
on outcomes of lower extremity bypass has also been in-
consistent. Some have demonstrated similar outcomes in
the setting of CLI between diabetic and nondiabetic pa-
tients,9,26,27 and others have noted lower limb salvage rates
or survival, or both.28,29 Among the largest reviews of
infrainguinal arterial bypass, consisting of 962 vein grafts in
843 patients, Akbari et al26 reported 5-year primary and
secondary graft patencies in diabetic patients of 75.6% and
77.0%, whereas those patencies for nondiabetic patients
were 71.9% and 73.6%. In comparison, our respective
endoluminal 5-year primary patencies were lower for both
NIDDM and IDDM groups, at 45%  9% and 57%  7%,
and our respective assisted primary patency rates were
58% 10% and 65% 7%. Similarly, primary and assisted-
primary patencies for non-diabetic patients in our study
were also lower at 30%  14% and 58%  8%. It should be
noted, however, that our rates are challenged at 5 years
because of the few patients at risk into this range of follow-up.
Akbari’s group also reported 5-year limb salvage in
diabetic patients of 87.3% compared with our own 5-yearlimb salvage of 31% 22% in NIDDM patients and 61%
8% in IDDM patients, rates that were significantly lower
than our 5-year limb salvage of 89%  4% for the nondia-
betic group. Wolfle et al9 reviewed 211 patients with CLI
and reported results consistent with Akbari et al in that their
1-year limb salvage rates were equivalent for diabetic and
nondiabetic patients, at 85% and 83%, respectively. Al-
though the results described by Wolfle et al, like those of
Akbari et al, are similar to our 1-year limb salvage of 89% for
the nondiabetic group, they are much higher than our
1-year NIDDM and IDDM results of 67% and 73%.
Our limb salvage results for the nondiabetic patients
presenting with CLI seem to be consistent with the limb
salvage rates reported by others for endovascular therapy
and are competitive with those reported for patients under-
going femorodistal bypass. In contrast, our limb salvage
rates for patients with DM are significantly lower than our
own rates for nondiabetic patients, as well as substantially
lower than the endovascular results for DM patients re-
ported by Dick et al24 and the femorodistal bypass results
for DMpatients reported by Akbari et al. It should be noted
that the results for Dick et al, like our own, involved
patients who were not randomly selected for endovascular
therapy, generating the possibility the selection differences
may account for differing results. Likewise, the results of
Akbari et al may selectively exclude patients who were not
an appropriate surgical risk owing to overall cardiovascular
disease burden and are therefore concentrated within en-
dovascular reports, such as our own. Nevertheless, based on
our results, we believe caution must be exercised in select-
ing diabetic patients with CLI for endovascular therapy
who are an appropriate surgical risk for femorodistal bypass.
An issue not specifically addressed by this study is the
role of tibial intervention in treating patients with CLI,
particularly those with DM. In our study, tibial runoff did
not differ between diabetic and nondiabetic groups when
analyzed within the mode of presentation. Accordingly,
tibial interventions were not significantly different between
groups. However, if diabetic and nondiabetic patient
groups are compared irrespective of mode of presentation,
we found that only 20% of nondiabetic patients had zero or
one tibial vessel runoff, whereas 31% of NIDDM patients
(P  .02) and 31% of IDDM patients (P  .02) had this
level of tibial runoff. Given the predilection for tibial vessel
involvement among diabetic patients with infrainguinal
atherosclerotic occlusive disease, it remains unclear if more
aggressive tibial angioplasty, particularly in the earlier por-
tion of this study, would elevate the limb salvage rate in our
diabetic patients.
It should be noted that by virtue of the primary strati-
fication, significant differences exist between patient popu-
lations that may be confounding variables. Our diabetic
patients were stratified into NIDDM and IDDM groups as
a surrogate for identifying those patients (IDDM) we be-
lieved likely to have greater insulin resistance, less endoge-
nous insulin reserve, and less well-controlled hyperglyce-
mia. Given the significance of these risk factors, particularly
compared with our nondiabetic patients, it is not surprising
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had significantly greater comorbidities. Notable among
these were higher rates of coronary and cerebrovascular
disease, hyperlipidemia, and dialysis-dependent end-stage
renal disease within the IDDM group. In addition, more
NIDDM patients had lesions categorized as TASC C or D
relative to the nondiabetic group among patients present-
ing with CLI. Curiously, the IDDM group had signifi-
cantly more TASC A or B lesions whether presenting with
claudication or CLI, a difference that may reflect more
significant microvascular deficiency leading to symptomatic
disease with less advanced femoropopliteal disease.
Selection bias may also have played a significant role in
IDDM TASC differences, in that operators may have cho-
sen femorodistal bypass for these patients in the presence of
more significant femoropopliteal lesions. Given the signif-
icance of some of these factors on Cox proportional hazards
analysis, our results must be interpreted with caution.
CONCLUSIONS
Among patients presenting with claudication, IDDM
confers an increased rate of restenosis that leads to signifi-
cantly decreased cumulative patency, even though these
patients more commonly present with less severe lesions by
TASC categorization. Nevertheless, most patients in all
groups had symptomatic improvement with low morbidity
and mortality, thus supporting the continued role of en-
doluminal therapy within this vascular bed in diabetic and
nondiabetic patients alike. Patients with CLI also had low
rates of complications; however, diabetic and nondiabetic
patients presenting with CLI and undergoing endovascular
therapy had equivalent restenosis and patency rates. Yet,
limb salvage rates were significantly lower for diabetic pa-
tients than nondiabetic patients. Given the limb salvage
results for historical controls of femorodistal bypass, one
must question the relative efficacy of endoluminal therapy
in appropriate surgical risk diabetic patients with CLI.
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Dr Bruce M. Elliott (Charleston, SC). I’d like to thank the
authors for providing me a copy of their manuscript prior to the
meeting and the Society for the honor of discussing their work
today. The authors assert that much has been published on lower
extremity bypass grafting and the corresponding impact of diabetes
on both patency and limb salvage rates. Despite recent zealous
enthusiasm for all things endovascular in the superficial femoral
artery, little has been written about the impact of diabetes on
endovascular interventions in the SFA.
The authors report a 20-year experience with 525 limbs in 427
patients undergoing endoluminal treatment of the SFA, entered
into their vascular registry database. One-half of the patients and
one-half of the limbs were in nondiabetic patients, while the
diabetic limbs were equally composed of insulin and non-insulin-
requiring diabetes. There were significantly more advanced comor-
bidities in the insulin-requiring diabetics than in the nondiabetics,
all associated with either reduced limb salvage or survival, notably
end stage renal disease and congestive heart failure.
The indications for intervention were significantly different
between patients with diabetes and those without. Only 25% of the
nondiabetic patients were treated for critical ischemia, while over
half of those with diabetes had critical ischemia and fully one-third
of those had tissue necrosis three times the incidence observed in
the non-diabetic patients. Despite the more advanced degree of
ischemia in those patients with diabetes as opposed to those
without, tibial outflow status and distribution of TASC A/B and
C/D lesions were seemingly unrelated.
Initial technical success was achieved in 93% of patients with-
out any difference between those with and without diabetes.
Although primary patency approximating 60% in 2 years was
equivalent in all groups and assisted patency only slightly worse in
those with insulin-requiring diabetes, limb salvage was substan-
tially worse in diabetic limbs as opposed to those without, 74%
versus 94% at two years.
The authors correctly observed, using Cox proportional haz-
ard analysis, that the more advanced the disease (ie, TASC C/D),
calcification, acute versus chronic occlusion or embolism, technical
complications such as perforation or embolization, all influencedserved, the presence of end-stage renal disease or dialysis indepen-
dently and negatively influenced limb salvage.
The authors conclude that endoluminal therapy for SFA oc-
clusive disease results in lower limb salvage rates for patients with
diabetes as compared to those without, despite similar patency
rates.
I have several questions for the authors. Was there a significant
difference in limb salvage between those with and without diabetes
who had tissue necrosis as their presenting symptom? Was there a
significant difference in limb salvage between those with and
without diabetes when matched for comparable TASC lesions and
tibial continuity? Did the location of the treated lesion, a proximal
SFA versus a distal SFA or popliteal lesion, influence outcome? And
finally, in how many patients were stents utilized, and were you
able to compare their results in similar TASC lesions between
diabetic patients and those without diabetes?
I’d like to thank the Society for the honor of discussing this
paper and congratulate the authors on a worthwhile endeavor.
Dr Andrew M. Bakken. With respect to your first question,
we did separate out the patients based on whether they had
claudication or critical ischemia. The limb salvage rates were sig-
nificantly reduced for diabetic groups in those presenting with
critical ischemia. We did not separate out those presenting with
tissue loss.
One of your follow-up questions was whether TASC lesions
severity impacted this or tibial continuity. The tibial outflow was
equivalent between all of our groups regardless of mode of presen-
tation. If we look specifically at those lesions that were TASC C or
D among the patients presenting with critical ischemia, reduced
limb salvage did persist. Among patients with TASC A or B lesions
presenting with critical ischemia, diabetes did not significantly
impact limb salvage.
With respect to the disease location, we did find a significant
association. Those patients presenting with critical ischemia had
greater below knee popliteal disease involvement and significantly
reduced limb salvage rates.
The final question related to stent usage. Overall stent usage in
these patients was about 37% and whether or not patients receiving
stents were diabetic fared better or worse than those who were not
diabetic was not shown to be significant.
roup.
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values for non-insulin-dependent diabetes mellitus (NIDDM) and insulin-dependent diabetes mellitus (IDDM)
groups are in comparison with the non-diabetic group. The number of patients “at risk” is listed at 6-month intervals
for each group.Table EI (online only). Patients presenting with
claudication—complications*
Complication Nondiabetic, % NIDDM, % IDDM, %
General
30-day mortality 1 2 0
Cardiac 1 0 0
Pulmonary 0 0 0
Renal 0 0 2
Infection 0 0 2
Site specific
Occlusion 4 4 7
Embolization 2 1 2
Dissection 7 1 0
Perforation 4 3 2
Access specific
Hematoma 6 3 4
Bleeding 1 0 0
Pseudoaneurysm 3 1 0
NIDDM, Non-insulin-dependent diabetes mellitus; IDDM, insulin-
dependent diabetes mellitus.
*P  .05 for all diabetic patient complications relative to nondiabetic
patients.
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Variables
Primary
patency Assisted patency
Free of
restenosis Limb salvage Survival
HR P HR P HR P HR P HR P
General
Male gender 0.83 .44 0.63 .11 0.93 .77 0.35 .07 1.66 .12
Current smoker 0.91 .78 0.75 .50 0.99 .98 0.85 .84 0.24 .09
Smoking history 1.42 .60 0.51 .32 1.04 .94 506178 .31 0.77 .81
CABG/PCI history 1.23 .40 0.94 .85 1.38 .17 3.63 .03 0.82 .54
Angina History 0.89 .64 0.60 .14 0.91 .71 1.03 .97 1.24 .46
Hypertension 1.00 .99 0.82 .66 1.10 .80 1619476 .07 3.80 .11
Hypothyroidism 0.66 .14 0.43 .03 0.60 .06 0.20 .07 1.03 .93
Hyperlipidemia 0.92 .71 0.61 .08 1.00 .99 1.85 .30 1.09 .77
ESRD 0.01 .32 0.01 .43 0.01 .32 0.01 .80 29.47 <.01
Site specific
TASC A 0.38 <.01 0.21 <.01 0.36 <.01 0.55 .32 0.59 .10
TASC B 1.20 .49 1.13 .70 1.17 .53 0.33 .21 1.80 .10
TASC C 1.29 .36 1.56 .19 1.54 .11 4.78 .03 1.39 .45
TASC D 5.01 <.01 6.35 <.01 5.03 <.01 2.69 .42 0.01 .18
Calcification 1.86 .03 1.83 .02 1.83 .02 1.00 .99 1.07 .90
Stent 0.92 .72 0.77 .38 1.09 .69 1.90 .30 1.94 .09
Tibial runoff
0 or 1 1.44 .19 1.66 .13 1.37 .23 3.08 .07 1.36 .36
2 or 3 0.69 .19 0.60 .13 0.73 .23 0.32 .07 0.73 .36
Tibial PTA 0.01 .66 0.01 .67 0.01 .66 1.00 1.00 0.01 .91
Complication
Acute occlusion 2.77 .04 4.99 .01 1.12 .02 0.01 .46 0.01 .26
Embolization 3.70 .07 5.28 .03 3.64 .07 12.90 .08 0.01 .56
Intimal flap 1.58 .55 2.94 .20 1.39 .66 0.01 .56 0.01 .32
Acute dissection 1.60 .39 1.04 .96 1.15 .82 0.01 .48 2.37 .30
Perforation 2.65 .10 1.38 .03 3.22 .03 6.71 .16 4.59 .09
Follow-up
Distal progression 1.78 .30 1.48 .61 1.20 .77 6.23 .06 2.82 .22
HR, Hazard ratio; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; ESRD, end-stage renal disease; PTA, percutaneous
transluminal angioplasty.
*Factors with significant association are in italic and boldface.Appendix Table EIII (online only). Patients presenting
with critical limb ischemia—complications*
Complication Nondiabetic, % NIDDM, % IDDM, %
General
30-day mortality 6% 5% 7%
Cardiac 1% 296 0%
Pulmonary 0% 0% 0%
Renal 1% 5% 0%
Infection 1% 0% 0%
Site specific
Occlusion 4% 6% 3%
Embolization 7% 6% 7%
Dissection 1% 8% 4%
Perforation 1% 3% 4%
Access specific
Hematoma 4% 2% 3%
Blooding 0% 0% 0%
Pseudoaneurysm 3% 2% 0%
NIDDM, Non-insulin-dependent diabetes mellitus; IDDM, insulin-
dependent diabetes mellitus.
*P  .05 for all diabetic patient complications relative to nondiabetic
patients.
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Variable
Primary patency Assisted patency Free of restenosis Limb salvage Survival
RR P RR P RR P RR P RR P
General
Male gender 1.11 .66 1.05 .85 1.02 .94 1.12 .73 0.71 .17
Current smoker 1.18 .64 1.14 .75 0.48 .15 0.90 .85 1.23 .63
Smoking history 1.10 .83 0.74 .52 1.00 .99 1.01 .99 3.38 .02
CABG/PCI history 1.33 .28 1.66 .08 1.42 .18 1.73 .11 2.07 .01
Angina history 0.81 .47 0.82 .56 0.57 .07 1.40 .38 0.68 .17
Hypertension 1.76 .15 1.28 .55 1.50 .28 0.95 .92 0.57 .10
Hypothyroidism 0.81 .46 0.99 .96 0.92 .76 0.91 .81 0.51 .03
Hyperlipidemia 0.78 .29 0.82 .45 0.91 .69 0.91 .76 1.71 .03
ESRD 1.46 .27 1.14 .75 1.50 .24 2.55 .02 3.50 .01
Site specific
TASC A 0.35 <0.01 0.36 <.01 0.34 <.01 0.99 .98 0.43 <.01
TASC B 0.98 .93 1.05 .88 0.95 .85 1.11 .77 1.42 .18
TASC C 1.59 .07 1.49 .18 1.62 .06 1.28 .49 1.73 .07
TASC D 2.37 <.01 2.11 .02 2.55 <.01 0.57 .25 1.57 .25
Calcification 1.22 <.01 3.08 .01 2.93 <.01 1.68 .31 1.29 .46
Stent 1.45 .12 1.11 .71 1.36 .20 1.05 .89 1.66 .07
Tibial runoff
0 or 1 1.53 .08 1.91 .02 1.51 .08 3.23 <.01 1.70 .03
2 or 3 0.63 .06 0.54 .02 0.63 .06 0.32 .01 0.56 .02
Tibial PTA 0.56 .37 0.36 .22 0.58 .41 1.10 .90 0.59 .58
Complication
Acute occlusion 3.85 <0.01 1.31 .52 3.82 <.01 2.90 .80 1.39 .60
Embolization 0.01 .21 0.01 .32 0.01 .18 0.01 .36 0.01 .13
Intimal flap 0.01 .21 0.01 .32 0.01 .18 0.01 .36 0.01 .13
Acute dissection 0.71 .62 0.97 .96 0.68 .57 1.31 .72 1.62 .39
Perforation 2.33 .21 1.81 .45 2.44 .19 0.79 .81 1.80 .14
Follow-up
Distal progression 1.46 .27 1.90 .09 1.64 .14 3.88 <.01 0.89 .75
HR, Hazard ratio; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; ESRD, end-stage renal disease; PTA, percutaneous
transluminal angioplasty.
*Factors with significant association are in italic and boldface.
